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Abstract
Background: Staphylococcus aureus is an important pathogen in paediatric patients with bloodstream infections.
The epidemiology of S. aureus bacteraemia, however, has not been well documented in children in South Africa.
Methods: A retrospective study was conducted at a children’s hospital in Cape Town, South Africa, to investigate the
epidemiology of S. aureus bacteraemia from 2007-2011. The incidence, clinical presentation, risk factors,
management and outcomes of methicillin sensitive S. aureus (MSSA) and methicillin resistant S. aureus (MRSA)
bacteraemia were compared.
Results: Over the five year study period, 365 episodes of S. aureus bacteraemia were identified. The annual
incidence was 3.28 cases per 1000 hospital admissions. MRSA was responsible for 26% of S. aureus bacteraemia
and 72% of nosocomial infections. Only six possible cases of community-acquired MRSA infections were described.
MSSA bacteraemia was more likely to present as pulmonary and bone or joint infections, while bacteraemia without a
source was the most common presentation with MRSA.  Infants, children with malnutrition, and residents of long-term
care facilities were at highest risk for MRSA bacteraemia. The overall case fatality rate for S. aureus bacteraemia
was 8.8% over five years, with MRSA being the only significant risk factor for mortality.
Conclusion: The incidence of S. aureus bacteraemia and MRSA bacteraemia in children has remained stable over
the past five years. MRSA is a predominantly nosocomial pathogen in children with S. aureus bacteraemia in Cape
Town, South Africa.
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Introduction
Staphylococcus aureus is a major human pathogen that
causes a wide variety of illnesses ranging from skin and soft
tissue infections to life-threatening invasive disease. This highly
adaptive organism is a significant source of bacteraemia,
responsible for both community-acquired and nosocomial
infections. Few South African studies have characterized the
contribution of S. aureus to bacteraemia in children. In Cape
Town, 11.6% of bacteraemia in hospitalized children were due
to S. aureus, while in specific cohorts of HIV-positive children,
10.6%, 11% and 15.7% of bacteraemic events were caused by
S. aureus [1-4].
Methicillin resistant S. aureus (MRSA) is one of the
commonest causes of healthcare-associated and nosocomial
infection amongst adults and children worldwide, and the
proportion of MRSA has been increasing over the last few
years [5]. In the only two paediatric studies in South Africa on
S. aureus infections, 2% of isolates were reported as MRSA at
Red Cross War Memorial Children’s Hospital in 1974, while a
second study, focusing on endocarditis in 36 children with SAB
in Johannesburg, noted that 31% of SAB were due to MRSA in
1995 [6,7]. More recently, an antimicrobial susceptibility study
on blood culture isolates from children and adults in South
African public hospitals in 2010, identified 30-60% of S. aureus
to be MRSA [8]. Similarly, two international multi-centre studies
reported MRSA to be responsible for 33% and 39% of S.
aureus infections in South Africa [9,10].
Since the late 1990’s, community-acquired MRSA (CA-
MRSA) infections have been reported to be rapidly emerging
[11]. CA-MRSA isolates are often associated with a distinct
antimicrobial sensitivity pattern and a different genetic
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background, although this distinction is becoming more blurred
as cases of HA-MRSA caused by strains with genotypes
similar to that described in CA-MRSA isolates have been
reported [12]. The prevalence of CA-MRSA varies widely
across the world. In South Africa, a study conducted in Cape
Town identified 10 possible CA-MRSA amongst 100 MRSA
isolates in adults and children while an adult study in
Johannesburg reported 20% of MRSA bacteraemia to have
originated from the community [13,14].
The aims of this study were to investigate the epidemiology
of SAB at a single children’s hospital in South Africa over a five
year period, and to describe the incidence, clinical
presentation, microbiologic profiles, risk factors, management
and outcomes of children with both methicillin-sensitive S.
aureus (MSSA) and MRSA bacteraemia.
Materials and Methods
Study population
This study was undertaken at Red Cross War Memorial
Children’s Hospital (RCWMCH), a tertiary level children’s
hospital in Cape Town, South Africa, which serves as a major
referral centre for children up to 13 years. The hospital does
not provide routine postnatal care or have a dedicated neonatal
intensive care facility.
Study design
A retrospective analysis was conducted of all paediatric
patients seen at RCWMCH with S. aureus bloodstream
infections between January 2007 and December 2011. All
patients from whom S. aureus had been isolated from blood
culture specimens over the five year period were identified
using the National Health Laboratory Service (NHLS)
database. Hospital clinical records were then retrospectively
examined. Data were collected on demographics, clinical
diagnosis, risk factors for infection, clinical and laboratory
markers of infection, antibiotic susceptibility profiles,
management of infection and clinical outcome.
Definitions
SAB was defined as the isolation of S. aureus from a blood
culture specimen. Isolates were identified and tested for
antimicrobial susceptibility at Groote Schuur Hospital NHLS
microbiology laboratory, according to the Clinical and
Laboratory Standards Institute guidelines appropriate for the
years in question [15]. Isolates were identified using the VITEK
2 system (BioMérieux, France). Antibiotic susceptibility was
determined using either standard Kirby Bauer disc diffusion, or
the automated VITEK 2 system [16]. The D-test for inducible
clindamycin resistance was performed on erythromycin
resistant isolates, and D-test positive isolates were reported as
clindamycin resistant. For MRSA isolates tested by disc
diffusion, vancomycin MICs were determined using the E-test
(BioMérieux, France). For isolates where susceptibility testing
was performed using the Vitek 2, the vancomycin MIC as
determined by the Vitek 2 was recorded. All S. aureus
organisms cultured from blood specimens were considered to
be clinically significant. However, multiple isolates of the same
organism from the same patients were excluded from analysis
if they were clinically deemed to be related to the incident
infection. The isolation of S. aureus from a blood culture drawn
more than 48 hours after admission to hospital, or drawn at
readmission within 48 hours of discharge, was considered to
be a nosocomial infection. Based on the definitions utilized by
the Centers for Disease Control and Prevention, healthcare-
associated infections were defined as those that occurred
within 48 hours of admission to hospital, with at least one of the
following healthcare-associated risk factors: hospitalization or
surgery within one year of onset of infection, presence of an
invasive device at the time of admission, resident of a long-
term care facility, and history of MRSA colonization or infection
[17]. Community-acquired MRSA infections were those
identified within 48 hours of hospital admission, but with none
of the aforementioned healthcare-associated risk factors.
Clinical diagnoses during the SAB episode were classified
according to the assessment of the attending physician in the
patient records. HIV infection was determined by HIV PCR
testing in children younger than 18 months, and by HIV ELISA
testing in children over 18 months. HIV exposure was identified
by history of maternal HIV infection, or a positive HIV antibody
test in infants less than 18 months who tested HIV PCR
negative. Leucocytosis was regarded as a white cell count
above the normal range for age according to the NHLS
reference standards. Malnutrition was defined according to
WHO growth standards as weight-for-height or height-for-age
z-score -2 SD below the mean WHO reference values. Severe
malnutrition was defined as weight-for-height or height-for-age
z score below -3SD of the mean, or by the presence of
nutritional oedema [18].
Statistical analysis
Weight-for-age z-scores (WAZ), height-for-age z-scores
(HAZ) and weight-for-height z-scores (WHZ) were calculated
using Epi-Info, version 3.5.3 (2011). Data were analysed using
Stata Statistical Software version 11.1 (StataCorp, College
Station, Texas). Non-parametric variables were evaluated with
Wilcoxon rank-sum tests and Kruskal-Wallis tests, and
categorical data with chi-square tests. Odds ratios, together
with 95% confidence intervals, were utilized to describe
measures of effect. For all analyses, p <0.05 was considered
statistically significant. Logistic regression was performed to
assess risk factors for MRSA infection and risk factors for
mortality. Variables with p <0.1 on univariate analysis were
selected for stepwise forward multivariate analysis.
Ethical considerations
The study was conducted in accordance with the Declaration
of Helsinki and was approved by the Departmental Research
Committee of the Department of Child and Adolescent Health,
and the Research Ethics Committee, Faculty of Health
Sciences, University of Cape Town (HREC REF:029/2011).
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Results
Incidence of infection
Between January 2007 and December 2011, 365 episodes
of S. aureus bacteraemia (SAB) were identified, 270 with
MSSA (74%) and 95 with MRSA (26%). S. aureus was isolated
on subsequent culture specimens, including blood, bone,
tissue, pus, pleural, pericardial, peritoneal and synovial fluids in
143/365 episodes (39%). Basic demographic (age, gender),
laboratory and microbiological data were accessible for all SAB
episodes. Unfortunately, due to the retrospective design of the
study, clinical and outcome data were not available for all
cases.
The annual incidence of SAB was 3.28 cases/1000 hospital
admissions per year with a mean frequency of 2.43 MSSA
cases and 0.85 MRSA cases per 1000 hospital admissions per
year. There was no significant change in the frequency of SAB
over the study period (p=0.38). While rates of MRSA infection
remained fairly constant from 2007-2011, the incidence of
nosocomial SAB rose steadily from 2007 and peaked in 2010
(Figure 1).
Figure 1.  Incidence of S. aureus bacteraemia (SAB) per 1000 hospital admissions.  
doi: 10.1371/journal.pone.0078396.g001
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Characteristics of study population
Demographic characteristics and basic infective markers of
the cohort are outlined in Table 1. The median age of patients
with staphylococcal bacteraemia was 11 months. Neonates
accounted for 36/365 (9.9%) of episodes while infants
represented 189/365 (51.8%) of SAB. Children with MRSA
infection were significantly younger (p=0.03), and more
frequently underweight (p=0.00) and stunted (p=0.00). In those
children whose HIV exposure and testing status was known, 51
(19.8%) were HIV-infected and 48 (19.4%) were HIV-exposed
but uninfected (Table 1). Notably 107 (29%) children had an
unknown HIV status. HIV infection, but not HIV exposure, was
significantly associated with MRSA bacteraemia (p=0.00).
Analysis of infective markers, including white cell count (WCC),
neutrophil count, band count and C-reactive protein (CRP),
revealed no differences between MSSA and MRSA
bacteraemia (Table 1).
Seventeen patients had two distinct episodes of SAB based
on isolation of the second organism more than 30 days after
the initial SAB episode and after completing an appropriate
course of antibiotic therapy. Six of these patients first had
MSSA followed by MRSA bacteraemia with a median of 51
days (range 4-278 days) between episodes. The remaining 11
patients are described in Table 2. Six patients had two
episodes of SAB more than 3 months apart (median 221 days;
range 101-807 days). The remaining 5 patients had a median
of 64 days (range 32-64 days) between the two episodes of
bacteraemia. However, as molecular typing was not available,
it was not possible to determine if these episodes were due to
re-infection with the same type of organism or a completely
new S. aureus infection.
Spectrum of S. aureus infections
The origin of SAB, was identifiable in 357/365 episodes: 33%
(118/357) were nosocomial, 16% (56/357) healthcare-
associated and 51% (183/357) community-acquired. MRSA
was responsible for 21% of healthcare-associated and 72% of
nosocomial infections. Six MRSA infections were classified as
community-acquired with no identifiable healthcare-associated
risk factors (one in 2007, one in 2009, three in 2010 and one in
2011). Primary diagnoses for these suspected CA-MRSA
cases were bacteraemia without identified source (4),
gastroenteritis (1) and superficial skin sepsis (1).
Data on clinical diagnosis, available for 337 episodes of SAB
(Table 3), showed that the most common clinical diagnosis was
SAB without an identifiable source (33%), followed by SAB with
pneumonia ± empyema (22%), SAB with skin and soft tissue
infections (17%) and SAB with bone or joint infections (12%).
Bloodstream infections without a source were more likely to be
MRSA infections, while pulmonary, bone and joint infections
were more likely to be due to MSSA. The only two bone or joint
infections caused by MRSA were nosocomial in origin. Central
venous catheter-related line sepsis was equally likely to be
attributable to MSSA or MRSA, although all were nosocomial in
origin (Table 3).
Table 1. Characteristics of patients with S. aureus
bacteraemia.
 All patients MSSA MRSA p
Median age in
months (IQR)
(n=365) (n=270) (n=95) 0.03
 11.3 (3.8-42.3) 14.0 (3.7-51.1) 7.1 (3.8-19.6)  
Male: Female 193:172 151:119 42:53 0.05
Median weight-for-
age z-score (IQR)











(n=331) (n=249) (n=82) 0.00
 131 (39.6%) 79 (31.7%) 52 (63.4%)  
Median height-for-
age z-score (IQR)









Stunted (%) (n=167) (n=103) (n=64) 0.00












HIV infection (%) (n=258) (n=179) (n=79) 0.00
 51 (19.8%) 26 (14.5%) 25 (31.6%)  
HIV exposed but
uninfected (%)
(n=248) (n=180) (n=68) ns
 48 (19.4%) 39 (21.7%) 9 (13.2%)  
Median white cell
count x 109/L (IQR)
(n=354) (n=262) (n=92) ns
 14.2 (9.3-20.8) 14.3 (8.9-20.4) 13.8 (9.7-21.6)  
Leucocytosis (%) (n=354) (n=262) (n=92) ns
 157 (44.4%) 123 (47%) 34 (37%)  
Median neutrophil
count x 109/L (IQR)
(n=277) (n=204) (n=73) ns
 5.6 (2.9-10.6) 5.5 (2.9-10.4) 5.7 (2.5-11.2)  
Median band count
x 109/L (IQR)
(n=268) (n=198) (n=70) ns
 1.7 (0.48-3.6) 1.7 (0.47-3.27) 1.9 (0.49-4.3)  
Median CRP mg/L
(IQR)




















(IQR = Interquartile range; CRP = C-reactive protein; ns= Not significant)
doi: 10.1371/journal.pone.0078396.t001
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Risk factors for MRSA infection
Univariate analysis showed that prior hospitalization within
one year, presence of an indwelling medical device, previous
MRSA infection, being a resident of a long-term care facility,
HIV infection, malnutrition, congenital cardiac disease,
concurrent tuberculosis, duration of incident hospitalization and
infancy (under 12 months), were significant risk factors for
MRSA infection (Table 4). On multivariate analysis, infancy,
resident of a long-term care facility, malnutrition, and longer
duration of incident hospitalization remained significant risk
factors.
Microbiologic profile
Results of antimicrobial susceptibility testing, available for all
365 isolates (Table 5), suggested that most MSSA isolates
were susceptible to the majority of antibiotics tested. Only 6%
of MSSA were susceptible to penicillin. Most MRSA isolates
displayed multi-drug resistance (Table 5). All MRSA were


















































































































BSI=Bloodstream infection; CVC=Central venous catheter; CCD=Congenital
cardiac disease; IV=Intravenous; PO=Per os
doi: 10.1371/journal.pone.0078396.t002
Table 3. Clinical diagnosis at the time of S. aureus
bacteraemia.
Clinical diagnosis at
the time of culture All MRSA MSSA OR (95%CI)
Bloodstream infection
with no source





73 (21.7%) 10 (12.2%) 63 (24.7%)
0.42
(0.18-0.89)*
Skin and soft tissue
infections
58 (17.2%) 18 (22%) 40 (15.7%) 1.51 (0.76-2.91)
Bone and joint
infections
39 (11.6%) 2 (2.4%) 37 (14.5%)
0.15
(0.02-0.60)*
Gastroenteritis 20 (5.9%) 2 (2.4%) 18 (7.1%) 0.33 (0.04-1.43)
Staph scalded skin
syndrome




11 (3.3%) 6 (7.3%) 5 (2%)
3.95
(0.97-16.74)
Endocarditis 8 (2.4%) 2 (2.4%) 6 (2.4%) 1.04 (0.10-5.95)
Meningitis 2 (0.6%) 1 (1.2%) 1 (0.4%)
3.14
(0.04-247.1)
Pericardial effusion 2 (0.6%) 0 2 (0.8%) -
Other 3 (0.9%) 0 3 (1.2%) -
TOTAL 337 (100%) 82 (100%) 255 (100%) -
*. (p<0.05)
doi: 10.1371/journal.pone.0078396.t003
Table 4. Risk factors for methicillin-resistant S. aureus
(MRSA) bacteraemia.
Risk factors for MRSA infection Univariate Analysis Multivariate analysis
 Odds Ratio (95% CI) Odds Ratio (95% CI)
Hospitalization within 1 year 2.89 (1.79-4.68)* 0.92 (0.41-2.06)
Surgery within 1 year 1.65 (0.94-2.91) 2.28 (0.73-7.10)
Indwelling device 2.02 (1.09-3.74)* 0.87 (0.25-3.10)
Prior MRSA infection 16.8 (4.7-60.11)* 6.54 (0.91-46.98)
Resident of a care facility 12.68 (4.04-39.76)* 47.94 (7.0-326.8)*
Gender 1.6 (0.99-2.56) 1.48 (0.69-3.14)
Age (infant vs. children >1 year) 2.05 (1.26-3.34)* 2.39 (1.07-5.38)*
Duration of incident hospitalization 1.06 (1.04-1.08)* 1.06 (1.03-1.09)*
HIV-infected 2.72 (1.45-5.12)* 1.84 (0.72-4.69)
HIV-exposed but uninfected 0.55 (0.25-1.21) -  
Malnutrition 4.45 (2.65-7.5)* 3.12 (1.40-6.96)*
Congenital cardiac disease 2.65 (1.30-5.38)* 0.37 (0.09-1.61)
Concurrent tuberculosis 6.76 (2.24-20.39)* 1.40 (0.23-8.44)
Chronic lung disease 1.53 (0.28-8.51) -  
Chronic renal disease 0.75 (0.21-2.74) -  
Malignancy 2.74 (0.89-8.38) -  
Burns 1.23 (0.37-4.01) -  
Long-term steroid/
immunosuppressant use
1.54 (0.38-6.29) -  
(*p<0.05)
doi: 10.1371/journal.pone.0078396.t004
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sensitive to vancomycin (minimal inhibitory concentration (MIC)
≤ 2μg/ml); three isolates were reported to have a vancomycin
MIC equal to 2μg/ml. All three cases were treated successfully
– catheter-related sepsis in a preterm infant with vancomycin
alone, pneumonia in an HIV-infected child with vancomycin and
clindamycin used sequentially, and bacteraemia without source
in a child with short bowel syndrome with a combination of
vancomycin and trimethoprim-sulfamethoxazole (TMP/SMX).
Compared to HIV-uninfected children, organisms isolated from
HIV-infected patients were more likely to be resistant to
TMP/SMX (63% vs. 21%) (p=0.00), gentamicin (55% vs. 24%)
(p=0.00) and rifampicin (51% vs. 16%) (p=0.00). Of the 32 HIV-
infected patients with TMP/SMX resistant isolates, 22 (69%)
were on TMP/SMX prophylaxis for Pneumocystis jirovecii at the
time of SAB. Antimicrobial resistance patterns were similar in
children who were HIV-exposed but uninfected, compared to
children who were not exposed to HIV.
Of the six MRSA isolates that were suspected to be
community-acquired, antimicrobial susceptibility patterns
showed that 4/6 (67%) were resistant to clindamycin and
erythromycin, 2/6 (33%) were resistant to TMP/SMX, 3/6 (50%)
were resistant to gentamicin, and 2/6 (33%) were resistant to
rifampicin. All six isolates were sensitive to vancomycin,
ciprofloxacin and fusidic acid.
In 84/365 (23%) of SAB episodes, a concomitant organism
was isolated on blood culture. Once typical skin contaminants
(coagulase negative staphylococci, Bacillus spp. and
Corynebacterium spp.) were excluded, 24/365 cultures (7%)
had a clinically significant second organism (polymicrobial
bacteraemia) – gram negative bacilli (10), Enterococcus
faecalis or faecium (9) and Streptococcus pyogenes or
agalactiae (5).. Infants (11%), children with malnutrition
Table 5. Antimicrobial susceptibility results of methicillin-
sensitive S. aureus (MSSA) and methicillin-resistant S.
aureus (MRSA) isolates and risk factors for mortality with S.
aureus bacteraemia.






Penicillin 255 (94.4) 270 95 (100) 95
Cloxacillin 0 (0) 270 95 (100) 95
Clindamycin 15 (5.6) 269 77 (81.9) 94
Erythromycin 18 (6.7) 269 80 (85.1) 94
TMP/SMX 29 (10.7) 269 57 (60.6) 94
Vancomycin 0 (0) 269 0 (0) 95
Ciprofloxacin 4 (1.5) 267 39 (41.9) 93
Gentamicin 22 (8.1) 268 70 (75.3) 93
Rifampicin 7 (2.6) 268 55 (59.1) 93
Fusidic acid 0 (0) 266 3 (3.2) 94
Moxifloxacin 0 (0) 28 4 (8.3) 48
Linezolid 0 (0) 128 0(0) 50
Teicoplanin 0 (0) 36 0 (0) 22
Tigecycline 0 (0) 28 0 (0) 19
doi: 10.1371/journal.pone.0078396.t005
(10.5%) and those with MRSA bacteraemia (12.6%) were more
likely to have a significant concomitant organism on culture. No
association was found between polymicrobial bacteraemia and
HIV infection or HIV exposure on chi-square analysis.
Antibiotic management
Data on appropriate antibiotic therapy, which was regarded
as the administration of antibiotics to which the organism was
sensitive, were available for 322 episodes. At the time the
culture was drawn, 31/322 (9.6%) were already on antibiotics
to which the organism was sensitive and likely to respond
clinically. The majority of these episodes (29/31; 94%) were
caused by MSSA and 25/31 (81%) were community-acquired
infections. Twelve of these patients received a dose of
intramuscular ceftriaxone for suspicion of severe bacterial
infection at a primary care clinic prior to transfer to RCWMCH,
in keeping with South African Integrated Management of
Childhood Illness guidelines [19]. The median time on therapy
before the blood culture was drawn was 6 hours (IQR 1.5-22.7
hours).
Excluding those who were already on antibiotics at the time
of culture, appropriate antibiotic therapy was instituted in
267/322 (82.9%) episodes of SAB. Time to appropriate therapy
was calculated if the precise time of blood draw and time of
antibiotic administration were documented. This information
was available in 141 episodes. Appropriate therapy was
initiated within a median time of 2.5 hours (IQR 0.7-8.5) in
MSSA and 46 hours (IQR 4.7-55.3) in MRSA infections
(p=0.00). The median time to initiation of therapy was 2.5 hours
for community-acquired infections, 5.8 hours for healthcare-
associated infections, and 10.6 hours for nosocomial infections
(p=0.00). There was no significant difference in time to therapy
when comparing episodes with an identified source of
bacteraemia and those without.
The remaining 24/322 episodes (7.5%) did not receive
appropriate antimicrobials. In 18/24 cases, the S. aureus
isolated was clinically regarded to be a contaminant. The
remaining six untreated patients died; in 5 cases, death
occurred before blood culture results became available while in
one case, the MRSA isolated was considered to be a
contaminant. Two deaths occurred upon arrival at RCWMCH
with pulmonary infections caused by MSSA noted on autopsy.
The remaining four deaths were related to MRSA bacteraemia
without a source; three of these were also malnourished.
Total treatment duration, which was known for 261 episodes,
varied according to the clinical diagnosis. The overall treatment
duration was 14 days (IQR 7-29 days). Endocarditis,
pulmonary and bone or joint infections were treated for a
median of 44 days (IQR 39-51 days), 13 days (IQR 7-23 days)
and 40 days (IQR 32-79 days) respectively. Central venous
catheter-related infections were treated for 16 days (IQR 13-28
days); 8/11 episodes required line removal due to recurrent
isolation of S. aureus. SAB without a source was treated for a
median of 9 days (IQR 6-14 days).
Outcomes
According to clinical records, 32 deaths were attributed to
SAB, resulting in a case fatality rate of 8.8% over the five year
Staphylococcus aureus Bacteraemia in Children
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period. Median time to death was 3.5 days (IQR 1.5-6.5 days).
SAB without a source accounted for 59% of deaths, while
pulmonary infection was responsible for an additional 25% of
mortality. There were no deaths attributed to central venous
catheter-related infection. MRSA accounted for 53% of deaths.
Factors contributing to mortality on univariate analysis included
MRSA infection (OR 3.71; CI 1.77-7.66), HIV infection (OR
2.91; CI 1.23-6.87) and malnutrition (OR 2.45; CI 1.17-5.12)
(Table 6). An identifiable source of SAB infection (OR 0.3; CI
0.14-0.62), and initiating appropriate antibiotic therapy within
eight hours of blood culture, had a protective effect (OR 0.32;
CI 0.13-0.77). Age, polymicrobial bacteraemia and the
occurrence of multiple positive cultures for S. aureus, were not
associated with mortality. On multivariate analysis, only MRSA
remained a significant risk factor for mortality (OR 3.76; CI
1.12-12.67).
Discussion
This report is the first comprehensive study of the
epidemiology of S. aureus bacteraemia in children in South
Africa. International trends show increasing reports of MRSA
bacteraemia in children over the last 20 years. In England and
Wales, a large multicenter study, reported an increase in the
proportion of MRSA bacteraemia from 0.9% in 1990 to 13% in
2000 [20]. In the United States, Wisplinghoff et al. (2003)
reported MRSA bacteraemia to have increased from 10% in
1995 to 29% in 2001 in 49 paediatric hospitals throughout the
country, while Burke et al. (2009) reported a similar increase of
9% in 2001 to 24% in 2006 in California [21,22]. No published
data are available for Africa on the trends of SAB in children. In
this study, the proportion of SAB and MRSA bacteraemia
remained fairly constant over the period 2007 to 2011.
However, the proportion of MRSA bacteraemia in children in
South Africa has shown a distinct upward trend from 2% in
1974, to 18% in 1992, to 26% in this study [1,6]. However, this
is lower than the 30-60% MRSA bacteraemia reported among
Table 6. Risk factors for mortality with S. aureus
bacteraemia.
Risk factors for Death Univariate Analysis Multivariate analysis
 Odds Ratio (95% CI)Odds Ratio (95% CI)
MRSA bacteraemia 3.71 (1.77-7.76)* 3.76 (1.12-12.67)*
HIV infection 2.91 (1.23-6.87)* 3.12 (0.99-9.78)
HIV exposed but uninfected 0.31 (0.07-1.40) ‐  
Malnutrition 2.45 (1.17-5.12)* 1.7 (0.49-5.81)
Age 0.84 (0.40-1.74)  
Gender 1.98 (0.94-4.19) 1.6 (0.52-4.92)
Appropriate antibiotics within 8 hours
of blood culture
0.32 (0.13-0.77)* 0.54 (0.17-1.67)
Identified source of infection 0.3 (0.14-0.62)* 0.39 (0.12-1.22)
Multiple positive cultures for S.
aureus
1.22 (0.59-2.55) ‐  
Polymicrobial bacteraemia 2.28 (0.81-6.44) -  
* (p<0.05)
doi: 10.1371/journal.pone.0078396.t006
adults and children in public sector hospitals in South Africa in
2010 [8].
Nosocomial and healthcare-associated infection accounted
for approximately half of all cases of SAB. The number of
cases of S. aureus bacteraemia acquired as nosocomial
infection, increased between 2009 and 2010 possibly due to a
concurrent measles epidemic in 2009-2010, and then declined
in 2011. There was a marked decline in the number of
healthcare-associated infections from 2008 to 2011. There was
no clear reason for this decline. Changes in S. aureus
colonization rates within the hospital may be responsible for
this observation, but further investigation is required. In this
study, MRSA was a predominantly nosocomial or healthcare-
associated pathogen. The proportion of CA-MRSA isolates
identified (6.3%), is lower than those of other South African
reports [13,14]. This study, however, focused on bloodstream
infections, while most cases of CA-MRSA have been reported
with skin and soft tissue infections. Due to the retrospective
study design, molecular typing was not available for the CA-
MRSA isolates.
As reported in other studies, infants are at greatest risk of
SAB, especially with regards to MRSA bacteraemia [20,23]. In
our cohort, they were also more likely to present with a
concomitant organism on blood culture. This susceptibility to
systemic bacterial illness may be attributed to the relative
immaturity of immune responses in infants. HIV-infected
children also have an increased risk of bacteraemia [24,25]. A
sizable proportion of our cohort (20%) was HIV-infected, of
which 49% had MRSA bacteraemia. Other South African
studies also demonstrated high proportions of MRSA in HIV-
infected children ranging from 77-100% [2-4]. This may be due
to the fact that HIV-infected children are more likely to be
hospitalized than other children. Several common infective
markers were also analyzed but were unable to distinguish
MSSA from MRSA bacteraemia (Table 1).
Bacteraemia without a source was the most common clinical
diagnosis. All community-acquired bone or joint infections were
MSSA in origin, which supports the empiric antibiotic choice of
cloxacillin for osteomyelitis and septic arthritis at RCWMCH.
Endocarditis was only diagnosed in 2.4% of episodes of SAB.
Although children in this study were not screened with
echocardiography, other studies have also shown that
endocarditis with SAB is an uncommon event in children
compared to adults [22,23,26].
As most episodes of MRSA bacteraemia were nosocomial or
healthcare-associated infections, the antimicrobial sensitivity
pattern reflected predominantly multi-drug resistant MRSA
isolates, which is in agreement with antimicrobial susceptibility
studies on both adults and children in South Africa [27,28]. All
isolates were susceptible to vancomycin, which remains the
drug of choice for managing MRSA infections in children. Low
rates of TMP/SMX and clindamycin susceptibility, limits the use
of these antibiotics until antimicrobial susceptibility results are
available for individual MRSA isolates. Notably, HIV-infected
children were observed to be infected with S. aureus isolates
that were more likely to be resistant to TMP/SMX, gentamicin
and rifampicin. This may be due to the widespread use of
TMP/SMX in most HIV-infected children for prophylaxis against
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Pneumocystis jiroveci infection, while gentamicin is a common
first line antibiotic agent for all children presenting to hospital
with sepsis. Many children with HIV are treated with rifampicin
for TB during their clinical course, which may account for the
high rates of rifampicin resistance in this cohort.
The median time to appropriate therapy in this study was
significantly delayed for MRSA infections, but this did not
impact on mortality. Identifying children with risk factors for
MRSA infection allows better guidance for empiric antibiotic
therapy for nosocomial and healthcare-associated infections. In
this setting, infants, malnourished children, and residents at
long-term care facilities should be treated with vancomycin as
part of their empiric antibiotic coverage for nosocomial infection
if S. aureus is considered likely, until results of antimicrobial
sensitivities are available. The recent clinical practice
guidelines, published by the Infectious Diseases Society for
America for the treatment of MRSA infections in adults and
children, advise treating uncomplicated SAB with at least 14
days of appropriate antibiotic therapy [29]. The treatment
duration for this category of patient was observed to be shorter
in our cohort. In our study it was not possible to determine if
shorter courses of treatment for SAB without a source were as
effective as two weeks of therapy.
The retrospective nature of the study imposed some
limitations. The number of SAB episodes reported may be an
underestimate of the true incidence of disease due to non-
standardized indications for blood culture, variability in blood
culture volumes collected in paediatric practice, and the
initiation of antibiotics in some cases prior to blood culture
collection. The absence of molecular typing of MRSA isolates
limited complete evaluation of the staphylococcal bacteramic
events, especially description of the CA-MRSA isolates.
Moreover, our study had a high rate of concomitant organisms
which were not excluded from analysis, as their presence on
blood culture did not preclude the presence of a significant
infection with S. aureus.
This study presents important clinical and epidemiological
information not previously available on S. aureus bacteraemia
in children in South Africa. Although rates of SAB and MRSA
bacteraemia were stable in our population, MRSA was a
significant source of nosocomial infection and was a major risk
factor for mortality in children with SAB. Prospective studies
that combine clinical and molecular epidemiology of S. aureus
infections in children are warranted.
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